LAB at a glance
STANDARD BIOTOOLS INC. (LAB, SEC CIK 1162194) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding STANDARD BIOTOOLS INC. (LAB) shares worth $72.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Carey Thomas D. on November 5, 2026 of 75,000 shares at $0.63 per share.
- In the last 90 days, LAB insiders reported 1 open-market purchase ($47K) and 0 open-market sales ($0) on Form 4, a net purchase of $47K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $85.3M
- −51.1% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$47K
- 13F holders
- 27 funds
- $72.7M · −1 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.02 · Item 7.01 · Item 5.07
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Merger agreement risk: representations and warranties expire at Closing, eliminating post-closing indemnification for undisclosed liabilities
- Legal risk: July and August 2026 stockholder demands could delay or enjoin the Merger
- CVR monetization risk: no payments if legacy-business proceeds, investment proceeds, contingent payments, and Parent Net Cash surplus are absent
- Dilution risk: CVR settlements may issue up to 76,000,000 combined-company shares
- Liquidity risk: unsecured CVRs are subordinated to senior obligations and lack an established trading market
Management Discussion & Analysis
- Revenue $19.385M, down $0.167M or 1% YoY, with instruments up 18% to $5.998M
- Gross margin 55.9% vs 48.5% YoY, gross profit $10.828M vs $9.484M
- Services and other revenue weakest line, down 12% to $5.057M; consumables down 4% to $8.330M
- Cash, cash equivalents and investments $559.4M vs $213.3M at December 31, 2025; operating cash use $63.1M
- Merger expected in fourth quarter of 2026; liquidity expected sufficient for at least the next 12 months
AI summary of the LAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved the Post-Closing Equity Incentive Plan and Post-Closing ESPP
- Both plans activate only if the merger closes, linking employee incentives to transaction completion
Item 7.01: Regulation FD Disclosure
- Stockholders approved all proposals at the November 19, 2026 Special Meeting
- Approval clears the company’s submitted corporate actions, with specific effects detailed in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- Special meeting quorum: 281.7M votes, representing 71.38% of voting power
- Merger share issuance approved: 274.1M for, 7.6M against, enabling Nasdaq-compliant equity consideration
Item EX-99.1: Item EX-99.1
- Stockholders approved all proposals for the Treeline Biosciences merger and Mass Cytometry business sale
- Treeline merger targeted for fourth quarter 2026, subject to customary closing conditions
Item 8.01: Other Events
- Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval
- 15 demand letters and two shareholder lawsuits allege material omissions, creating litigation, delay and transaction-cost risks
Item 7.01: Regulation FD Disclosure
- Microfluidics business sale to ARCHIMED closed on November 3, 2026
- Transaction completes Standard BioTools’ previously announced divestiture and transfers future business ownership to ARCHIMED
Item EX-99.1: Item EX-99.1
- ARCHIMED completed the acquisition of Standard BioTools’ Microfluidics Business, separating it from LAB’s operating portfolio
- Business relaunched as Biomark Scientific, retaining the Biomark platform, Biomark X9 system and existing team
AI summaries of LAB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LAB
Don't miss the next LAB filing
- Alerts as it files. A push when LAB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LAB, by share count.
- Ask anything. An AI agent that reads every LAB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Carey Thomas D. | Buy | Nov 5, 2026 | 75,000 | $0.63 |
| Kim Hanjoon Alex | F | Aug 20, 2026 | 28,195 | $0.67 |
| Mackay Sean | F | Aug 20, 2026 | 25,729 | $0.67 |
| Egholm Michael | F | Aug 20, 2026 | 97,627 | $0.67 |
| Egholm Michael | F | Aug 3, 2026 | 362,625 | $0.87 |
| Kim Hanjoon Alex | F | Jul 23, 2026 | 202,476 | $0.90 |
| Mackay Sean | A | Jun 20, 2026 | 500,000 | - |
| Cox Troy | A | Jun 18, 2026 | 175,923 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $174.4M | $85.3M |
| Gross Profit | - | $84.3M | $42.5M |
| Operating Income | - | -$175.2M | -$110.2M |
| Net Income | - | -$138.9M | -$74.9M |
| Gross Margin | - | 48.3% | 49.9% |
| Op. Margin | - | -100.5% | -129.2% |
| Net Margin | - | -79.6% | -87.8% |
| Balance Sheet | |||
| Total Assets | $323.1M | $612.3M | $567.8M |
| Equity | - | $471.7M | $424.3M |
| ROE | - | -29.4% | -17.7% |
| Per Share | |||
| EPS | - | $-0.52 | $-0.20 |
| Cash Flow | |||
| Operating CF | - | -$143.5M | -$74.3M |
| CapEx | $2.8M | $8.4M | $8.3M |
Source: XBRL data in STANDARD BIOTOOLS INC. (LAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LAB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $72.7M |
| Q2 2026 | 28 | $81.1M |
| Q1 2026 | 28 | $108.7M |
| Q4 2025 | 26 | $165.5M |
| Q3 2025 | 25 | $162.7M |
| Q2 2025 | 26 | $150.8M |
| Q1 2025 | 22 | $116.1M |
| Q4 2024 | 19 | $171.0M |
- D.E. Shaw & Co+1.22M (+43%)
- Renaissance Technologies LLC+1.05M (+106%)
- Vanguard Capital Management LLC+244.0K (+2%)
- Citadel Advisors LLC+220.9K (+9%)
- Invesco Ltd+155.7K (+70%)
- Millennium Management−2.98M (-85%)
- AQR Capital Management−1.30M (-95%)
- Northern Trust−93.1K (-12%)
- State Street Corp−83.6K (-5%)
- Morgan Stanley−55.8K (-2%)
- Two Sigma Investments+1.20M
- Allstate−14.2K
- FMR LLC (Fidelity)−3.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LAB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jul 27, 2026 | - | - | - |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
LAB SEC filings: frequently asked questions
Are LAB insiders buying or selling?
In the last 90 days, STANDARD BIOTOOLS INC. (LAB) officers, directors and 10% owners reported 1 open-market purchase worth $46,898 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LAB stock?
As of September 30, 2026, the largest STANDARD BIOTOOLS INC. (LAB) holders among the 13F filers tracked by SignalX were Viking Global Investors ($43.4 million), Vanguard Capital Management LLC ($9.3 million), BlackRock ($6.1 million), D.E. Shaw & Co ($3.0 million), Morgan Stanley ($2.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LAB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), STANDARD BIOTOOLS INC. (LAB) reported revenue of $85.3 million (down 51.1% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$0.20. The figures come from the XBRL data in the 10-K.
What did LAB report in its latest 8-K?
STANDARD BIOTOOLS INC. (LAB) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 7.01 (Regulation FD Disclosure) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved the Post-Closing Equity Incentive Plan and Post-Closing ESPP.
What are the latest LAB SEC filings?
STANDARD BIOTOOLS INC. (LAB) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 5, 2026.
What is LAB's SEC CIK number?
STANDARD BIOTOOLS INC. (LAB)'s SEC Central Index Key (CIK) is 1162194. EDGAR lists every LAB filing under that number.
Ask anything about LAB
The research agent reads LAB's filings, financials, insider trades and 13F holders, then answers with sources.